Literature DB >> 8938628

Telomere length in human liver diseases.

Y Urabe1, K Nouso, T Higashi, H Nakatsukasa, N Hino, K Ashida, N Kinugasa, K Yoshida, S Uematsu, T Tsuji.   

Abstract

To determine the role of telomere-mediated gene stability in hepatocarcinogenesis, we examined the telomere length of human liver with or without chronic liver diseases and hepatocellular carcinomas (HCC). The mean telomere restriction fragment (TRF) length of normal liver (n = 13), chronic hepatitis (n = 11), liver cirrhosis (n = 24) and HCC (n = 24) was 7.8 +/- 0.2, 7.1 +/- 0.3, 6.4 +/- 0.2 and 5.2 +/- 0.2 kb, respectively (mean +/- standard error). TRF length decreased with a progression of chronic liver diseases and that in HCC was significantly shorter than that in other chronic liver diseases (p < 0.05). The ratios of TRF length of HCC to that of corresponding surrounding liver of well differentiated (n = 7), moderately differentiated (n = 10) and poorly differentiated (n = 4) HCCs were 0.83 +/- 0.06, 0.75 +/- 0.05 and 0.98 +/- 0.09, respectively. The ratio of poorly differentiated HCC was significantly higher than that of moderately differentiated HCC (p < 0.05). A comparison between the size and telomere length ratio of moderately differentiated HCCs revealed a decrease of the ratio with size until it reached 50 mm in diameter. In contrast, the ratio increased as the size enlarged over 50 mm. These findings suggest that the gene stability of the liver cells mediated by the telomere is reduced as chronic liver disease progresses and that telomerase is activated in poorly differentiated HCC and moderately differentiated HCC over 50 mm in diameter.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938628     DOI: 10.1111/j.1600-0676.1996.tb00748.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  26 in total

Review 1.  Advances in gene therapy of liver cirrhosis: a review.

Authors:  W J Dai; H C Jiang
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 2.  How long should telomeres be?

Authors:  A Aviv; C B Harley
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 3.  Telomeres and telomerase in cancer.

Authors:  Steven E Artandi; Ronald A DePinho
Journal:  Carcinogenesis       Date:  2009-11-03       Impact factor: 4.944

4.  Relative telomere length: a novel non-invasive biomarker for the risk of non-cirrhotic hepatocellular carcinoma in patients with chronic hepatitis B infection.

Authors:  Xiaoying Fu; Shaogui Wan; Hie-Won Hann; Ronald E Myers; Richard S Hann; Jennifer Au; Bicui Chen; Jinliang Xing; Hushan Yang
Journal:  Eur J Cancer       Date:  2012-03-21       Impact factor: 9.162

5.  The Spectrum of Hepatic Involvement in Patients With Telomere Disease.

Authors:  Devika Kapuria; Gil Ben-Yakov; Rebecca Ortolano; Min Ho Cho; Or Kalchiem-Dekel; Varun Takyar; Shilpa Lingala; Naveen Gara; Michele Tana; Yun Ju Kim; David E Kleiner; Neal S Young; Danielle M Townsley; Christopher Koh; Theo Heller
Journal:  Hepatology       Date:  2019-04-10       Impact factor: 17.425

Review 6.  Telomere shortening as genetic risk factor of liver cirrhosis.

Authors:  Lucia Carulli
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

7.  Digital image analysis of the distribution of proliferating cell nuclear antigen in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Authors:  Gerond Lake-Bakaar; Vito Mazzoccoli; Lynda Ruffini
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

8.  Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis.

Authors:  R Sato; C Maesawa; K Fujisawa; K Wada; K Oikawa; Y Takikawa; K Suzuki; H Oikawa; K Ishikawa; T Masuda
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 9.  Telomeres, stem cells, senescence, and cancer.

Authors:  Norman E Sharpless; Ronald A DePinho
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

Review 10.  Telomere and telomerase in chronic liver disease and hepatocarcinoma.

Authors:  Lucia Carulli; Claudia Anzivino
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.